On Demand Webinar: A New Multiplexed SARS-CoV-2 Serological Assay using Advanced Flow Cytometry
Antibodies focused against the receptor binding domain (RBD) of the SARS-CoV-2 Spike protein demonstrate powerful neutralizing activity. Several classes of these antibodies have been recognized in COVID-19 patients. These neutralizing antibodies are greatly responsible for the protective immunity induced by the current COVID-19 vaccines. Hence there is a constant need to accurately determine the quantity and duration of the antibody response against the SARS-CoV-2 Spike RBD.
Combined detection of three isotypes (IgG, IgM and IgA) of anti-SARS-CoV-2 Spike RBD antibodies in a single well of a 96- or 384-well plate, saves time and precious patient samples, and also provides a comprehensive dynamic profile of the humoral response over time, as a consequence of natural infection with SARS-CoV-2 or immunization with COVID-19 vaccines.
This webinar introduces the newly developed, validated kit, which provides a robust, rapid and sensitive serological assay for the simultaneous measurement of IgG, IgM and IgA anti-SARS-CoV-2 Spike RBD antibodies in a single sample of human plasma or serum, with detection levels in the pg/mL range.
The webinar includes:
- A discussion on the value of assessing levels of the three major isotypes of anti-SARS-CoV-2 Spike RBD antibodies, to characterize the type and kinetics of the antibody response to COVID-19 vaccination or infection.
- Details of how the SARS-CoV-2 (IgG, IgM and IgA) kit and iQue® Advanced Flow Cytometry Platform, are able to perform multiplexed assessment of the three major isotypes of anti-SARS-CoV-2 Spike RBD antibodies.
About the speaker
Dr. Julie Lovchik
Scientist | Assay Development, Sartorius
Dr. Julie Lovchik received her BS from Wichita State University and her Ph.D. in immunology from the University of Texas Southwestern Medical Center in Dallas where she focused on identifying T cell-mediated effector mechanisms involved in protection against pathogens.
She has post-doctoral experience at the University of New Mexico School of Medicine and the Experimental Immunology Branch at the National Cancer Institute. She was then appointed as a Research Assistant Professor at the University of New Mexico Health Sciences Center, and spent over 15 years managing a CDC-registered ABSL-3/Select Agent lab where she conducted research focused on understanding host-pathogen interactions, along with the development and evaluation of therapeutics and vaccines for high-risk respiratory pathogens under several DARPA, DTRA, and NIH/NIAID contracts geared toward providing pharmaceutical/biotech companies a first step in meeting FDA regulations for demonstrating drug efficacy.
She is experienced in the use of flow cytometry, secreted protein analysis, and various in vitro and in vivo immunology models. Currently, she is working as a Scientist at Sartorius where she is developing reagents for the iQue® Advanced Flow Cytometry Platform.